Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short-term Investments (2020 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Short-term Investments for 5 consecutive years, with $36000.0 as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 9.09% to $36000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36000.0 through Dec 2025, up 9.09% year-over-year, with the annual reading at $36000.0 for FY2025, 9.09% up from the prior year.
  • Short-term Investments hit $36000.0 in Q4 2025 for Ani Pharmaceuticals, roughly flat from $36000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $5.0 million in Q4 2022 to a low of $33000.0 in Q4 2024.
  • Historically, Short-term Investments has averaged $2.3 million across 4 years, with a median of $36000.0 in 2025.
  • Biggest five-year swings in Short-term Investments: decreased 0.04% in 2021 and later rose 9.09% in 2025.
  • Year by year, Short-term Investments stood at $5.0 million in 2021, then rose by 0.1% to $5.0 million in 2022, then crashed by 99.34% to $33000.0 in 2024, then increased by 9.09% to $36000.0 in 2025.
  • Business Quant data shows Short-term Investments for ANIP at $36000.0 in Q4 2025, $36000.0 in Q3 2025, and $36000.0 in Q2 2025.